<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Annett</forename><surname>Linge</surname></persName>
							<email>annett.linge@uniklinikum-dresden.de</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="department" key="dep2">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>partner site Dresden</addrLine>
									<settlement>Heidelberg, Germany</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">OncoRay -National Center for Radiation Research in Oncology</orgName>
								<orgName type="institution" key="instit2">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit3">Technische Universität Dresden</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department" key="dep1">Department of Radiotherapy and Radiation Oncology</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit2">Technische Universität Dresden</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="laboratory">National Center for Tumor Diseases (NCT)</orgName>
								<address>
									<addrLine>partner site Dresden</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ulrike</forename><surname>Schötz</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>partner site Munich</addrLine>
									<settlement>Heidelberg</settlement>
									<country>Germany, and, Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="department">Department of Radiotherapy and Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">University Hospital</orgName>
								<orgName type="institution" key="instit2">Ludwig-Maximilians-Universität</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="department">Department of Radiotherapy and Radiooncology</orgName>
								<orgName type="institution" key="instit1">Philipps-University Marburg</orgName>
								<orgName type="institution" key="instit2">University Hospital Gießen and Marburg</orgName>
								<address>
									<settlement>Marburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Steffen</forename><surname>Löck</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="department" key="dep2">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>partner site Dresden</addrLine>
									<settlement>Heidelberg, Germany</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">OncoRay -National Center for Radiation Research in Oncology</orgName>
								<orgName type="institution" key="instit2">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit3">Technische Universität Dresden</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department" key="dep1">Department of Radiotherapy and Radiation Oncology</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit2">Technische Universität Dresden</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="laboratory">National Center for Tumor Diseases (NCT)</orgName>
								<address>
									<addrLine>partner site Dresden</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Fabian</forename><surname>Lohaus</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="department" key="dep2">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>partner site Dresden</addrLine>
									<settlement>Heidelberg, Germany</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">OncoRay -National Center for Radiation Research in Oncology</orgName>
								<orgName type="institution" key="instit2">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit3">Technische Universität Dresden</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department" key="dep1">Department of Radiotherapy and Radiation Oncology</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit2">Technische Universität Dresden</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="laboratory">National Center for Tumor Diseases (NCT)</orgName>
								<address>
									<addrLine>partner site Dresden</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cläre</forename><surname>Von Neubeck</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="department" key="dep2">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>partner site Dresden</addrLine>
									<settlement>Heidelberg, Germany</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">OncoRay -National Center for Radiation Research in Oncology</orgName>
								<orgName type="institution" key="instit2">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit3">Technische Universität Dresden</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Volker</forename><surname>Gudziol</surname></persName>
							<affiliation key="aff10">
								<orgName type="laboratory">National Center for Tumor Diseases (NCT)</orgName>
								<address>
									<addrLine>partner site Dresden</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="department" key="dep1">Department of Otorhinolaryngology</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit2">Technische Universität Dresden</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alexander</forename><surname>Nowak</surname></persName>
							<affiliation key="aff10">
								<orgName type="laboratory">National Center for Tumor Diseases (NCT)</orgName>
								<address>
									<addrLine>partner site Dresden</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department">Department of Oral and Maxillofacial Surgery</orgName>
							</affiliation>
							<affiliation key="aff15">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit2">Technische Universität Dresden</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Inge</forename><surname>Tinhofer</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="department" key="dep2">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>partner site Berlin</addrLine>
									<settlement>Heidelberg, Germany</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="department">Department of Radiooncology and Radiotherapy</orgName>
								<orgName type="institution">Charité University Medicine Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Volker</forename><surname>Budach</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="department" key="dep2">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>partner site Berlin</addrLine>
									<settlement>Heidelberg, Germany</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="department">Department of Radiooncology and Radiotherapy</orgName>
								<orgName type="institution">Charité University Medicine Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ali</forename><surname>Sak</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>partner site Essen</addrLine>
									<settlement>Heidelberg</settlement>
									<country>Germany, Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff17">
								<orgName type="department" key="dep1">Department of Radiotherapy</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">University of Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Stuschke</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>partner site Essen</addrLine>
									<settlement>Heidelberg</settlement>
									<country>Germany, Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff17">
								<orgName type="department" key="dep1">Department of Radiotherapy</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">University of Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Panagiotis</forename><surname>Balermpas</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="department" key="dep2">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>partner site</addrLine>
									<settlement>Heidelberg, Germany, Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff18">
								<orgName type="department">Department of Radiotherapy and Oncology</orgName>
								<orgName type="institution">Goethe-University</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Claus</forename><surname>Rödel</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="department" key="dep2">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>partner site</addrLine>
									<settlement>Heidelberg, Germany, Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff18">
								<orgName type="department">Department of Radiotherapy and Oncology</orgName>
								<orgName type="institution">Goethe-University</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hatice</forename><surname>Bunea</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="department" key="dep2">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>partner site Freiburg</addrLine>
									<settlement>Heidelberg, Germany</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff19">
								<orgName type="department" key="dep1">Department of Radiation Oncology</orgName>
								<orgName type="department" key="dep2">Medical Center</orgName>
								<orgName type="department" key="dep3">Medical Faculty</orgName>
								<orgName type="institution">University of Freiburg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anca-Ligia</forename><surname>Grosu</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="department" key="dep2">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>partner site Freiburg</addrLine>
									<settlement>Heidelberg, Germany</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff19">
								<orgName type="department" key="dep1">Department of Radiation Oncology</orgName>
								<orgName type="department" key="dep2">Medical Center</orgName>
								<orgName type="department" key="dep3">Medical Faculty</orgName>
								<orgName type="institution">University of Freiburg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Amir</forename><surname>Abdollahi</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff20">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="laboratory">National Center for Radiation Research in Oncology (NCRO)</orgName>
								<orgName type="institution" key="instit1">Heidelberg Institute of Radiation Oncology (HIRO)</orgName>
								<orgName type="institution" key="instit2">University of Heidelberg Medical School</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff21">
								<orgName type="department" key="dep1">Heidelberg Ion Therapy Center (HIT)</orgName>
								<orgName type="department" key="dep2">Department of Radiation Oncology</orgName>
								<orgName type="institution">University of Heidelberg Medical School</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff22">
								<orgName type="department" key="dep1">National Center for Tumor Diseases (NCT)</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">University of Heidelberg Medical School</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff23">
								<orgName type="department" key="dep1">Translational Radiation Oncology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">University of Heidelberg Medical School</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jürgen</forename><surname>Debus</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff20">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="laboratory">National Center for Radiation Research in Oncology (NCRO)</orgName>
								<orgName type="institution" key="instit1">Heidelberg Institute of Radiation Oncology (HIRO)</orgName>
								<orgName type="institution" key="instit2">University of Heidelberg Medical School</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff21">
								<orgName type="department" key="dep1">Heidelberg Ion Therapy Center (HIT)</orgName>
								<orgName type="department" key="dep2">Department of Radiation Oncology</orgName>
								<orgName type="institution">University of Heidelberg Medical School</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff22">
								<orgName type="department" key="dep1">National Center for Tumor Diseases (NCT)</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">University of Heidelberg Medical School</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff24">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="laboratory">Clinical Cooperation Unit Radiation Oncology</orgName>
								<orgName type="institution">University of Heidelberg Medical School</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ute</forename><surname>Ganswindt</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>partner site Munich</addrLine>
									<settlement>Heidelberg</settlement>
									<country>Germany, and, Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="department">Department of Radiotherapy and Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">University Hospital</orgName>
								<orgName type="institution" key="instit2">Ludwig-Maximilians-Universität</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kirsten</forename><surname>Lauber</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>partner site Munich</addrLine>
									<settlement>Heidelberg</settlement>
									<country>Germany, and, Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="department">Department of Radiotherapy and Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">University Hospital</orgName>
								<orgName type="institution" key="instit2">Ludwig-Maximilians-Universität</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Steffi</forename><surname>Pigorsch</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>partner site Munich</addrLine>
									<settlement>Heidelberg</settlement>
									<country>Germany, and, Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff25">
								<orgName type="department">Department of Radiation Oncology</orgName>
								<orgName type="institution">Technische Universität München</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stephanie</forename><forename type="middle">E</forename><surname>Combs</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>partner site Munich</addrLine>
									<settlement>Heidelberg</settlement>
									<country>Germany, and, Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff25">
								<orgName type="department">Department of Radiation Oncology</orgName>
								<orgName type="institution">Technische Universität München</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Mönnich</surname></persName>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="department" key="dep2">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg, Germany, Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff26">
								<orgName type="department" key="dep1">Department of Radiation Oncology</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="department" key="dep3">Institute of Pathology</orgName>
								<orgName type="department" key="dep4">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">University Hospital Tübingen</orgName>
								<orgName type="institution" key="instit2">Eberhard Karls Universität Tübingen</orgName>
								<address>
									<country>Germany; aa</country>
								</address>
							</affiliation>
							<affiliation key="aff27">
								<orgName type="department">ab Tumour-and Normal Tissue Bank</orgName>
								<orgName type="institution" key="instit1">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit2">Technische Universität Dresden</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff28">
								<orgName type="department">Medical Systems Biology</orgName>
								<orgName type="laboratory">ac University Cancer Centre (UCC)</orgName>
								<orgName type="institution" key="instit1">University Cancer Centre (UCC)</orgName>
								<orgName type="institution" key="instit2">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit3">Technische Universität Dresden</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff29">
								<orgName type="institution" key="instit1">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit2">Technische Universität Dresden</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff30">
								<orgName type="department" key="dep1">Institute of Radiooncology -OncoRay</orgName>
								<orgName type="department" key="dep2">ae German Cancer Research Center (DKFZ)</orgName>
								<orgName type="laboratory">af Clinical Cooperation Group Personalized Radiotherapy in Head and Neck Cancer</orgName>
								<orgName type="institution">Helmholtz-Zentrum Dresden -Rossendorf</orgName>
								<address>
									<settlement>Dresden, Heidelberg</settlement>
									<country>Germany;, Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff31">
								<orgName type="institution">Helmholtz Zentrum Munich</orgName>
								<address>
									<settlement>Neuherberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff32">
								<orgName type="department" key="dep1">Department of Radiation Oncology</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">OncoRay -National Center for Radiation Research in Oncology</orgName>
								<orgName type="institution" key="instit2">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit3">Technische Universität Dresden</orgName>
								<address>
									<addrLine>Fetscherstraße 74</addrLine>
									<postCode>01307</postCode>
									<settlement>Dresden</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">50FA1673D877B10B92BB6A444D00C70B</idno>
					<idno type="DOI">10.1016/j.radonc.2017.12.007</idno>
					<note type="submission">Received 10 October 2017 Received in revised form 11 December 2017 Accepted 12 December 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:38+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>DKTK-ROG HNSCC HPV</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Objective: To compare six HPV detection methods in pre-treatment FFPE tumour samples from patients with locally advanced head and neck squamous cell carcinoma (HNSCC) who received postoperative (N = 175) or primary (N = 90) radiochemotherapy.</s><s>Materials and methods: HPV analyses included detection of (i) HPV16 E6/E7 RNA, (ii) HPV16 DNA (PCRbased arrays, A-PCR), (iii) HPV DNA (GP5+/GP6+ qPCR, (GP-PCR)), (iv) p16 (immunohistochemistry, p16 IHC), (v) combining p16 IHC and the A-PCR result and (vi) combining p16 IHC and the GP-PCR result.</s><s>Differences between HPV positive and negative subgroups were evaluated for the primary endpoint loco-regional control (LRC) using Cox regression.</s><s>Results: Correlation between the HPV detection methods was high (chi-squared test, p &lt; 0.001).</s><s>While p16 IHC analysis resulted in several false positive classifications, A-PCR, GP-PCR and the combination</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Loco-regional control p16 Radiochemotherapy of p16 IHC and A-PCR or GP-PCR led to results comparable to RNA analysis.</s><s>In both cohorts, Cox regression analyses revealed significantly prolonged LRC for patients with HPV positive tumours irrespective of the detection method.</s><s>Conclusions: The most stringent classification was obtained by detection of HPV16 RNA, or combining p16 IHC with A-PCR or GP-PCR.</s><s>This approach revealed the lowest rate of recurrence in patients with tumours classified as HPV positive and therefore appears most suited for patient stratification in HPVbased clinical studies.</s></p><p><s>Ó 2017 Elsevier B.V. All rights reserved.</s><s>Radiotherapy and Oncology xxx (2018) xxx-xxx Head and neck squamous cell carcinoma (HNSCC) is the 6th leading cancer worldwide <ref type="bibr" target="#b0">[1]</ref>.</s><s>While the number of cases related to tobacco smoking history and alcohol consumption is remaining stable or is even decreasing <ref type="bibr" target="#b1">[2]</ref>, the incidence of human papilloma virus (HPV)-driven tumours, especially in the subgroup of oropharyngeal squamous cell carcinomas (OPSCC), is steadily increasing <ref type="bibr" target="#b2">[3]</ref>.</s><s>Previous studies showed that patients with HPV positive HNSCC have a better overall survival (OS) compared to patients with HPV negative tumours <ref type="bibr" target="#b3">[4]</ref>.</s><s>In preclinical studies, HPV-infected cell lines derived from primary HNSCC displayed a higher degree of radiosensitivity <ref type="bibr" target="#b4">[5]</ref> which appears to be related to impairments in DNA repair <ref type="bibr" target="#b5">[6]</ref>.</s><s>Furthermore, the HPV status has also been identified as a robust prognostic factor of loco-regional control (LRC) in patients with HNSCC who received primary <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref> as well as postoperative radio(chemo)therapy <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b12">13]</ref>.</s><s>Due to the better outcome of patients with HPV positive HNSCC compared to patients with HPV negative HNSCC, the HPV status is considered as one of the biomarkers, which allows for risk stratification in personalized radiation oncology (reviewed in <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b14">15]</ref>).</s><s>Better outcome has mainly been reported for patients with HPV positive OPSCC <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b16">17]</ref>.</s><s>In this regard, a number of clinical trials have been initiated in order to assess whether patients with HPV-driven OPSCC may benefit from radiation dose de-escalation with the aim of reducing adverse effects while maintaining comparable clinical outcome (www.</s><s>clinicaltrials.gov;</s><s>e.g.</s><s>NCT01088802, NCT01530997, NCT01687413, NCT02281955, NCT03396718).</s></p><p><s>HPV infection typically appears in small defects of the basal epithelium.</s><s>Only if the target cell is mitotically active, new HPV virions can be synthesized.</s><s>In contrast to most viral infections, HPV DNA synthesis is fully dependent on the DNA replication machinery of the host cells <ref type="bibr" target="#b17">[18]</ref>.</s><s>The HPV E7 oncoprotein is of particular relevance for HNSCC pathogenesis via a deregulation cell cycle control.</s><s>HPV E7 targets members of the retinoblastoma (Rb) family and mediates their subsequent degradation.</s><s>In turn, E2 transcription factors are activated resulting in expression of S-phase-related genes and thus cell cycle progression <ref type="bibr" target="#b18">[19]</ref>.</s><s>This functional inactivation of the Rb-pathway finally leads to p16 over-expression -a phenomenon which is commonly used as surrogate marker for HPV infection in HNSCC (reviewed in <ref type="bibr" target="#b19">[20]</ref>).</s><s>In addition, the HPV E6 oncoprotein initiates ubiquitylation and subsequent proteasomal degradation of p53, impaired activation of p21, and finally uncontrolled cell cycle progression.</s><s>Accordingly, it is of similar relevance for HNSCC pathogenesis as HPV E7 <ref type="bibr" target="#b19">[20,</ref><ref type="bibr" target="#b20">21]</ref>, and detection of HPV E6 and/or E7 is frequently used for diagnostic purposes <ref type="bibr" target="#b21">[22]</ref>.</s></p><p><s>To date, various HPV detection strategies guided by the biology of HPV-induced carcinogenesis are available, including detection of (i) HPV DNA, (ii) viral E6/E7 mRNA (from transcriptionally active HPV infection), and (iii) p16 over-expression as a result of altered cell cycle control <ref type="bibr" target="#b22">[23,</ref><ref type="bibr" target="#b23">24]</ref>.</s><s>The accepted gold standard for the identification of clinically relevant HPV infections is the detection of viral E6/E7 mRNA in fresh or frozen tumour material using polymerase-chain reaction (PCR) and more recently, fluorescence in situ hybridization (FISH) analysis <ref type="bibr" target="#b22">[23,</ref><ref type="bibr" target="#b24">25]</ref>.</s><s>Since fresh or frozen tumour material is not routinely available, and mRNA isolation from formalin-fixed and paraffin-embedded (FFPE) tissues and the subsequent PCR are technically challenging <ref type="bibr" target="#b22">[23]</ref>, detection of p16 over-expression by IHC is being used as a surrogate marker for HPV infection alone or in combination with assessment of HPV DNA using different PCR-based approaches in a number of clinical studies and meanwhile also in clinical routine (reviewed in <ref type="bibr" target="#b22">[23,</ref><ref type="bibr" target="#b23">24]</ref>).</s><s>So far, it has not been systematically analysed which of the methods is the most reliable one for patient stratification with particular focus on the response to radio(chemo)therapy, i.e. in a field where an increasing number of trials are currently undertaken and critically require precise means of HPV status detection.</s></p><p><s>Therefore, the overall aim of this study was to compare six methods, which are available for HPV status analysis in pretreatment FFPE samples of HNSCC and to evaluate the results in connection with the clinical outcome of radio(chemo)therapy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Material and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients</head><p><s>In this retrospective multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG), two previously published patient cohorts were examined <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b11">12]</ref>.</s><s>All patients had been diagnosed with locally advanced HNSCC and were treated with state-of-the-art contemporary treatment schedules, either by curatively intended primary radiochemotherapy (RCTx) or surgery followed by postoperative RCTx (PORT-C) at one of the eight DKTK partner sites.</s><s>Treatments and patient inclusion followed narrow stratification criteria <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b11">12]</ref> with a minimum follow-up of 24 months.</s><s>Staging was based on the UICC TNM classification, 7th edition (2009).</s><s>Data and biomaterial collection have been previously described in detail <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b11">12]</ref>.</s><s>Briefly, patients of the postoperative cohort presented with a tumour stage pT4 and/or &gt;3 positive lymph nodes and/or positive microscopic resection margins and/or extracapsular spread.</s><s>In the primary cohort, patients usually presented with inoperable HNSCC.</s><s>In this analysis, patients from both cohorts were included if sufficient biomaterial was available to perform all six HPV detection methods (postoperative: 175 out of 221 patients, primary: 90 out of 158 patients).</s><s>Patients' characteristics are summarized in Table <ref type="table" target="#tab_0">1</ref>.</s><s>Characteristics of all patients, including those who did not meet the inclusion criteria because of insufficient biomaterial for the completion of all six methods, are summarized in Supplementary Table <ref type="table" target="#tab_0">1</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Preparation of biomaterials for HPV analysis</head><p><s>Formalin-fixed and paraffin-embedded (FFPE) material of the primary tumour collected prior to radiotherapy was subjected to staining with haematoxylin and eosin, followed by histological evaluation and confirmation for the presence of squamous cell carcinoma and a minimum tumour content of 5%.</s><s>Afterwards, the FFPE blocks were processed for biomaterial preparation under standardized conditions.</s><s>p16 immunohistochemistry (p16 IHC) Immunohistochemistry staining for p16 was performed using the CINtec Histology Kit (Roche mtm laboratories AG, Basel, CH) as described previously <ref type="bibr" target="#b11">[12]</ref>.</s><s>Tumours with a strong and diffuse nuclear and cytoplasmic staining intensity in !70% of the tumour cells were defined as p16 positive tumours <ref type="bibr" target="#b3">[4]</ref>.</s><s>All samples were evaluated by two independent observers (AL and CvN) with an inter-observer variability of &lt;5%.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Extraction of genomic DNA and RNA</head><p><s>Extraction of genomic DNA (gDNA) and total RNA from FFPE tumour material has been described previously <ref type="bibr" target="#b11">[12]</ref>.</s><s>Briefly, gDNA was extracted using the QIAamp DNA FFPE tissue kit (Qiagen GmbH, Hilden, DE) according to the instructions of the manufacturer, aliquoted and stored at À20 °C until further use.</s><s>Total RNA was extracted using the fully automated Tissue Preparation System (TPS; Siemens Healthcare Diagnostics, Tarrytown, NY) following the instructions of the manufacturer, aliquoted and stored at À80 °C until required.</s><s>DNA and RNA quantities were estimated using the Qubit fluorometer (Life Technologies GmbH, Darmstadt, DE).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>HPV DNA assessment using PCR-based array (A-PCR)</head><p><s>HPV DNA analyses were carried out using the LCD-Array HPV 3.5 kit (CHIPRON GmbH, Berlin, DE) as described previously <ref type="bibr" target="#b11">[12]</ref>.</s><s>Briefly, PCR was carried out using Primer Mix A (My 11/09) and B ('125') provided with the kit, and the HotStarTaq Plus Master Mix (Qiagen GmbH).</s><s>Hybridization mix including 5 ml of each amplified PCR products A and B as well as a positive control (UT-SCC-45 xenografted tumour, HPV33 positive) and a negative control (RNase-free water; Qiagen GmbH) was added to the respective field of the LCD-Array.</s><s>The hybridization spots were scanned and analysed using the SlideReader Software (CHIPRON).</s><s>For internal quality control purposes, input DNA control was performed using 10 ng of the respective gDNA and 0.8 mM of b-globin specific primers (forward: 5 0 -TTGGACCCAGAGGTTCTTTG-3 0 , reverse: 5 0 -CACT CAGTGTGGCAAAGGTG-3 0 ) in 25 ml final volume of HotStarTaq Plus Master Mix (Qiagen GmbH).</s><s>The PCR conditions were as follows: 95 °C for 5 min followed by 38 cycles (60 s at 94 °C, 60 s at 58 °C and 60 s sat 71 °C).</s><s>In order to exclude any inhibition of the HPV-specific PCR, spike-in controls (10 ng gDNA of UT-SCC-45 xenografted tumour) were performed using the Primer Mix B as described above, and PCR-products were evaluated semiquantitatively on agarose gels.</s></p><p><s>HPV DNA assessment using GP5+/GP6+ qPCR (GP-PCR) GP-PCR was performed with 1.85-10.6</s><s>ng gDNA extracted from FFPE samples and 900 nM primers as previously described <ref type="bibr" target="#b25">[26,</ref><ref type="bibr" target="#b26">27]</ref> in 20 ml final volume of 1x Maxima SYBR Green (Thermo Fisher, Heidelberg, Germany) and a cycling protocol of initial 10 s at 95 °C followed by 45 cycles (15 s 95 °C, 30 s 54 °C, 15 s 72 °C) on an LC480 Real-time PCR platform (Roche Applied Science, Penzberg, Germany).</s><s>HeLa cell gDNA (positive for HPV 18) served as positive control.</s><s>Input DNA control was carried out using 1.85-10.6</s><s>ng gDNA and 75 nM of 18S rDNA specific primers (forward: 5 0 -CGGC TACCACATCCAAGGAA-3 0 , reverse: 5 0 -GCTGGAATTACCGCGGCT-3 0 ) in 20 ml final volume of 1x Maxima SYBR Green and a cycling protocol of 95 °C for 10 s, and 45 cycles (15 s at 95 °C, 30 s at 60 °C).</s><s>To exclude the presence of PCR inhibitors in the extracts, spike-in controls were performed: 1 ng of HeLa DNA was added to each sample, and the difference in Cp values compared to the spike-in control alone was calculated (DCp = Cp spike-in sample À Cp mean spike-in controls ).</s></p><p><s>Only samples with positive 18S rDNA signal were further evaluated using GP5+/GP6+ qPCR (Supplementary Fig. <ref type="figure" target="#fig_1">1A</ref>).</s><s>Samples with positive HPV qPCR signal were considered HPV gDNA positive.</s><s>Samples with negative HPV qPCR signal were further subjected to the spike-in control PCR, and samples with DCp values &gt;5 were excluded from the analyses due to poor sample quality (Supplementary Fig. <ref type="figure" target="#fig_1">1B</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>HPV16 RNA analysis using nanoString technology (HPV16 E6/E7)</head><p><s>To determine HPV16 E6/E7 RNA expression levels, total RNA was subjected to nanoString analysis (nanoString Technologies, Seattle, WA, USA).</s><s>nanoString analysis has been performed as described previously <ref type="bibr" target="#b27">[28]</ref>.</s><s>Raw counts were logarithmized followed by normalization to the mean of the reference genes ACTR3, B2M, GNB2L1, NDFIP1, POLR2A, RPL11 and RPL37A.</s><s>RNA expression of HPV16 E6/E7 revealed two separated clusters of tumours, see Supplementary Fig. <ref type="figure" target="#fig_2">2</ref>.</s><s>These clusters were labelled as HPV16 E6/ E7 RNA negative and HPV16 E6/E7 RNA positive, respectively.</s><s>Tumours positive for both, HPV E6 and HPV E7 RNA were classified as HPV16 RNA positive.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical endpoints and statistical analyses</head><p><s>The primary endpoint of this study was LRC.</s><s>Freedom from distant metastases (FDM) and OS were considered as secondary endpoints.</s><s>All endpoints were calculated from the first day of radiotherapy until occurrence of the event of interest or censoring.</s><s>The corresponding survival curves were estimated by the Kaplan-Meier method and compared by Log-rank tests.</s><s>In addition, the impact of the HPV status on the endpoints was evaluated using univariable and multivariable Cox-regression.</s><s>In multivariable regression, one HPV parameter was included together with extracapsular extension (ECE) status and tumour localization (oropharynx vs oral cavity and hypopharynx) for the postoperative cohort and with N stage (0,1 vs 2,3) and the natural logarithm of the gross tumour volume (GTV) for the primary cohort.</s><s>These parameters were previously shown to be associated with outcome for the patient cohorts reported here <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b11">12]</ref>.</s><s>Correlations between the different methods for analysis of HPV status were illustrated by contingency tables and analysed by chi-squared tests.</s><s>Statistical analyses were performed using IBM SPSS Statistics 24 (IBM Corporation, Armonk, NY).</s><s>For all analyses, two-sided tests were performed and p-values &lt;0.05 were considered statistically significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>In this retrospective study, patients with locally advanced HNSCC from two previously published cohorts treated by stateof-the-art approaches were included <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b11">12]</ref>.</s><s>The first cohort received PORT-C (N = 175) while the second cohort was treated using primary RCTx (N = 90).</s></p><p><s>The postoperative cohort included 100 patients (57.1%) with OPSCC, 49 (28%) with oral cavity carcinomas and 26 (14.9%) with hypopharyngeal carcinomas (Table <ref type="table" target="#tab_0">1</ref>).</s></p><p><s>Immunohistochemical analysis showed p16 over-expression in 63 cases (36.0%).</s><s>By using the HPV DNA PCR-based array method (A-PCR), HPV DNA was detected in 59 cases including 57 HPV16 DNA (32.6%)</s><s>cases as well as 1 HPV18 DNA and 1 HPV33 DNA positive case, whereas the HPV DNA GP5+/GP6+ qPCR method (GP-PCR) revealed HPV positivity in 51 cases (29.1%).</s><s>The HPV16 RNA method showed 49 positive cases (28.0%).</s><s>In the primary cohort, 40 patients (44.4%) with OPSCC, 15 (16.7%) with oral cavity carcinomas and 35 (38.9%) with hypopharyngeal carcinomas were included (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Assessment of p16 over-expression revealed 13 positive cases (14.4%).</s><s>The A-PCR method showed 14 HPV DNA positive cases including 12 HPV16 DNA (13.3%)</s><s>and 2 HPV33 DNA positive cases.</s><s>The GP-PCR method revealed 13 positive cases (14.4%).</s><s>HPV16 RNA positivity was detected in 9 cases (10.0%).</s><s>The results of the different methods correlated significantly (p &lt; 0.001 for all comparisons; Tables <ref type="table" target="#tab_2">2 and 3</ref>).</s><s>For the postoperative cohort, out of the 49 HPV16 RNA positive cases, 48 were also positive using GP-PCR and 46 were positive using A-PCR (Table <ref type="table" target="#tab_1">2</ref>).</s><s>In the primary cohort, only 9 HPV16 RNA positive cases were observed.</s><s>All of these cases were also positive for HPV DNA as assessed by A-PCR or GP-PCR.</s><s>However, in the A-PCR or GP-PCR subgroups, additional 3 or 4 positive cases were detected, respectively (Table <ref type="table" target="#tab_2">3</ref>).</s></p><p><s>Out of the 49 HPV16 RNA positive cases in the postoperative cohort, 47 showed also p16 over-expression.</s><s>However, 16 out of 63 p16 positive cases were found to be negative for HPV16 RNA, including 9 OPSCC and 7 tumours in the oral cavity.</s><s>Out of 49 cases that were positive for HPV16 RNA, 45 were positive for p16 and HPV16 DNA (A-PCR) and 46 were positive for p16 and HPV DNA (GP-PCR) simultaneously (Table <ref type="table" target="#tab_1">2</ref>).</s><s>In the primary cohort, all HPV16 RNA positive tumours were p16 positive, while overexpression of p16 was seen in additional 4 cases.</s><s>When combining p16 and HPV DNA (A-PCR or GP-PCR), tumours were classified almost identically to HPV16 RNA (Table <ref type="table" target="#tab_2">3</ref>).</s><s>p16 protein overexpression was further analysed together with the keratinization of those tumours <ref type="bibr" target="#b28">[29]</ref>.</s><s>In the postoperative cohort, 57.1% of the p16 positive tumours and 76.8% of the p16 negative tumours were keratinized (p = 0.007).</s><s>As expected, keratinization was found to be negatively associated with HPV positivity.</s><s>Out of the 27 p16 positive, non-keratinizing tumours, 24 were found to be positive for HPV DNA (A-PCR or GP-PCR).</s><s>Similar results were obtained for HPV16 RNA (23 tumours).</s><s>However, these 23 tumours represent only 47% of all HPV16 RNA positive tumours.</s><s>In the primary cohort, keratinization was found in 30.9% of the p16 positive and 53.2% of the p16 negative tumours (p = 0.13).</s><s>Here, 8 out of the 9 p16 positive, non-keratinizing tumours were found to be positive for HPV DNA (A-PCR or GP-PCR) and 7 for HPV RNA.</s><s>The HPV classification of the subgroup of patients with OPSCC was also assessed and revealed a similar agreement between the six methods (Supplementary Tables <ref type="table" target="#tab_2">2 and 3</ref>), since the majority of the HPV positive tumours were OPSCC (postoperative cohort: $80%, primary cohort: $75%).</s></p><p><s>Concerning the correlation to outcome, all of the four methods and the two combinations of p16 and HPV DNA status revealed statistically significant associations of the HPV status with LRC (Fig. <ref type="figure" target="#fig_1">1</ref>) but also with OS and FDM in the postoperative cohort (Supplementary Figs. <ref type="figure">3 and 5</ref>) for all patients (left columns).</s><s>In the primary cohort, HPV DNA status was significantly associated with LRC (p = 0.016 for A-PCR; p = 0.033 for GP-PCR; Log-rank test; Fig. <ref type="figure" target="#fig_2">2</ref>).</s><s>In the subgroups positive for p16, HPV16 RNA or combined p16 and HPV DNA (both, A-PCR or GP-PCR-based methods), no locoregional recurrence (LRR) occurred.</s><s>Results for OS and FDM are shown in Supplementary Figs. <ref type="figure">4 and 6</ref>.</s><s>For both cohorts different methods for the determination of the HPV status led to similar patient stratifications regarding LRC (Figs. <ref type="figure" target="#fig_2">1 and 2</ref>) and OS (Supplementary Figs. <ref type="figure">3 and 4</ref>), respectively.</s><s>This is also summarized in Supplementary Fig. <ref type="figure">7</ref>, which shows the 5-year LRC for the patients with HPV positive tumours vs the number of HPV positive tumours for each method.</s><s>For the secondary endpoint FDM similar results were achieved by all six methods, while significance was only reached in the postoperative cohort (Supplementary Fig. <ref type="figure">5</ref>).</s><s>This may be due to the lower number of HPV positive tumours and the low incidence of distant metastases in the primary cohort (Supplementary Fig. <ref type="figure">6</ref>).</s><s>Limiting the cohorts to patients with OPSCC led to similar results (right columns of Figs. <ref type="figure" target="#fig_2">1, 2</ref> and Supplementary Figs.</s><s><ref type="figure">3-6</ref>).</s><s>The results of univariable and multivariable Cox regression are presented in Supplementary Table <ref type="table">4</ref> and Table <ref type="table">4</ref>, respectively.</s><s>Multivariable regression revealed that HPV status is an important prognostic factor independent of tumour localization and ECE status on the postoperative cohort and of N stage and tumour volume on the primary cohort.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>This is the first study investigating the relative power of different HPV biomarkers for the outcome of postoperative or primary radio(chemo)therapy using patient cohorts that followed narrow inclusion criteria and were treated with state-of-the-art contemporary treatment schedules.</s><s>Clinically, this kind of methodological comparison is urgently needed, because there are several ongoing prospective trials which aim at personalizing radio(chemo)therapy in patients with OPSCC based on the HPV status and employ different means of detection.</s></p><p><s>This multicentre contemporary study compared six approaches for the determination of the HPV status and its association with LRC, FDM and OS after PORT-C or primary RCTx in patients with locally advanced HNSCC including OPSCC but also oral cavity and hypopharyngeal squamous cell carcinomas, using pre-treatment FFPE material of the primary tumour.</s><s>It showed that all six meth-Table <ref type="table">4</ref> Multivariable Cox regression of loco-regional control, freedom from distant metastases and overall survival for the postoperative and primary cohort.</s><s>In each model one HPV parameter was combined with tumour localization (oropharynx vs oral cavity and hypopharynx) and ECE status for the postoperative cohort and with N stage (0,1 vs 2,3) and the logarithm of tumour volume for the primary cohort.</s><s>Only the result for the HPV parameter is reported.</s><s>HR = hazard ratio; 95% CI = 95 percentage confidence interval; ECE = extracapsular extension.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Loco-regional control</head><p><s>Freedom ods yield similar results and thus apparently are able to stratify patients into those with HPV positive and HPV negative HNSCC.</s></p><p><s>In the subgroup of patients with OPSCC, 80% of p16 positive tumours were also positive for HPV16 DNA, whereas other tumour locations revealed HPV16 DNA positivity in only 50% of the p16 positive cases, showing that the technology may not be equally suited for all tumour locations.</s><s>HPV E6/E7 mRNA assessment meanwhile has emerged as the gold standard.</s><s>It is recommended to be performed by FISH analysis <ref type="bibr" target="#b24">[25]</ref>, since PCR turned out to be considerably more error-prone.</s><s>However, both methods are not routinely being used for HPV detection in the clinical routine.</s><s>To the best of our knowledge, this is the first study using another hybridization-based technique (nanoString technology) for HPV RNA assessment on FFPE samples, which are routinely obtained for diagnostic purposes.</s><s>In our cohorts, cases positive for HPV E6/E7 RNA revealed a better LRC with only two LRR within the postoperative cohort and no LRR in the primary cohort within the HPV positive subgroup.</s><s>In clinical routine, p16 over-expression is widely being used as a surrogate marker for HPV infection due to its easy feasibility and a rather robust sensitivity of 95-100%.</s><s>However, since p16 is also involved in other biological processes like cellular senescence, the specificity of this method for the detection of HPV-driven tumours is limited to 85-95% <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref>.</s><s>The erroneous classification of false-positive tumours undoubtedly needs to be avoided -particularly in the context of HPV-based patient stratification for deescalation trials.</s><s>In an attempt to identify false-positive HPV tumours based on p16 over-expression, it has been suggested to include the keratinization of the respective tumours <ref type="bibr" target="#b28">[29]</ref>.</s><s>However, we could not observe an additional benefit.</s><s>Another drawback is that so far no standardized cut-off for the identification of p16 over-expressing tumours is available, although 70% positivity is widely being accepted (reviewed in <ref type="bibr" target="#b31">[32]</ref>).</s><s>To improve the accuracy of the HPV detection, p16 over-expressing tumours are often being subjected to HPV DNA analysis by PCR-based methods <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b23">24]</ref> or HPV DNA in situ -hybridization methods <ref type="bibr" target="#b32">[33]</ref>.</s><s>In our study, the application of this combination led to similar results as HPV RNA analysis alone.</s><s>In the postoperative cohort, three LRR were detected in p16 positive cases, which were reduced to one LRR when combined with the HPV16 DNA status (A-PCR).</s><s>However, by combining p16 with HPV16 DNA status, also the number of positive cases was reduced from 63 to 48 such that the relative fraction of LRR in the positive groups decreased less clearly (from 4.8% to 4.2%).</s><s>In the primary cohort, no LRR occurred in HPV RNA positive tumours or in p16 and HPV DNA positive tumours (A-PCR and GP-PCR based methods).</s><s>Similar results were also observed for the secondary endpoint OS <ref type="bibr" target="#b3">[4]</ref>.</s></p><p><s>In terms of PCR-based HPV DNA analysis, we compared two methods that are being used in the daily routine.</s><s>Although the HPV DNA array-based method is capable of detecting 32 genotypes simultaneously, most clinical evidence is currently available for the HPV16 DNA genotype.</s><s>To the best of our knowledge this is also the only genotype that has been described as a causative agent in the development of HNSCC to date <ref type="bibr" target="#b33">[34]</ref>.</s><s>Therefore, the classification related to the HPV16 DNA status was included in this study.</s><s>The GP5+/GP6+ qPCR-based method enables the concomitant detection of 11 genotypes <ref type="bibr" target="#b25">[26,</ref><ref type="bibr" target="#b26">27]</ref> and revealed as expected, similar results comparable results to the HPV DNA array-based method.</s><s>Concerning patient stratification with respect to LRC and OS both analyses led to similar results in both patient cohorts, with the majority of them reaching statistical significance.</s><s>However, A-PCR based detection identified more positive cases than the GP-PCR based method on the postoperative cohort, while their results were similar on the primary cohort.</s><s>In contrast, HPV RNA analysis revealed less HPV positive cases in both cohorts.</s><s>Concerning patient stratification by means of carrying the transcriptionally active virus (HPV RNA or combinations of p16 IHC with A-PCR or GP-PCR) versus no or inactive virus (p16 IHC or A-PCR or GP-PCR), the methods show variations in their detection power (see Supplementary Fig. <ref type="figure">7</ref>).</s><s>Although DNA-PCR based methods and p16 IHC are capable of detecting above 90% of HPV RNA positive tumours, there is an additional subset of RNA-negative cases detected as being HPV positive and this subset can only be minimized by combining the two methods.</s><s>Therefore, only the HPV RNA hybridization-based method or the two combinations of A-PCR or GP-PCR with p16 IHC can be recommended for stratification purposes of patients regarding HPV-driven tumours.</s><s>The determination of patients with HPV-driven rather than HPV-positive tumours seems to be especially relevant for oropharyngeal tumours, since OPSCC with sole p16 over-expression have been reported to show a genetic pattern that is similar to that of HPV negative OPSCC <ref type="bibr" target="#b34">[35]</ref>.</s><s>In general, the reported HPV positivity of OPSCC in the primary cohort is rather low compared to the OPSCC in the postoperative cohort (22.5% vs 73%), which may be due to the correlation of the HPV status and the T stage: In the primary cohort the T stage of OPSCC is significantly higher than in the postoperative cohort (p &lt; 0.001).</s><s>At the same time HPV positive tumours have a significantly lower T stage (p = 0.002), which is in line with the literature <ref type="bibr" target="#b3">[4]</ref>.</s><s>Hence, patients with HPV positive tumours are more likely to receive surgery followed by postoperative radiotherapy, whereas larger tumours are often functionally inoperable.</s></p><p><s>For further patient stratification beyond the HPV status, additional biomarker analyses are currently being carried out within this DKTK-ROG study covering multiple radiobiological aspects <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref>.</s></p><p><s>Taken together, the determination of the HPV status by HPV RNA or by the combination of p16 IHC and HPV DNA analysis led to comparable results regarding HPV classification.</s><s>However for clinical routine, the combined analyses (p16 IHC followed by PCR-based method) seem to be advantageous with respect to its feasibility in routine laboratories.</s><s>To validate the small differences between the methods, larger patient cohorts are required.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 1 .</head><label>1</label><figDesc><div><p><s>Fig.1.</s><s>Kaplan-Meier estimates of loco-regional control (LRC) of all patients with locally advanced HNSCC (left column) and of patients with oropharyngeal tumours only (right column), who received PORT-C.</s><s>(A,B) HPV16 RNA analysis, (C,D) HPV16 DNA using A-PCR, (E,F) HPV DNA analysis using GP-PCR, (G,H) p16, (I,J) both p16 and A-PCR and (K,L) both p16 and GP-PCR.</s><s>Patient groups were compared by log-rank tests.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 2 .</head><label>2</label><figDesc><div><p><s>Fig.2.</s><s>Kaplan-Meier estimates of loco-regional control (LRC) of all patients with locally advanced HNSCC (left column) and of patients with oropharyngeal tumours only (right column), who received primary RCTx.</s><s>(A,B) HPV16 RNA analysis, (C,D) HPV16 DNA using A-PCR, (E,F) HPV DNA analysis using GP-PCR, (G,H) p16, (I,J) both p16 and A-PCR and (K,L) both p16 and GP-PCR.</s><s>Patient groups were compared by log-rank tests.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Patient characteristics of both cohorts, including patients for whom all HPV analyses were performed.</s><s>LN = lymph nodes.</s></p></div></figDesc><table><row><cell>Postoperative cohort</cell><cell>Primary cohort</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Correlation of different methods for the determination of HPV status for the postoperative cohort (p &lt; 0.001 for all).</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell>A-PCR</cell><cell></cell><cell>GP-PCR</cell><cell></cell><cell>p16</cell><cell></cell><cell cols="2">p16 and A-PCR</cell><cell cols="2">p16 and GP-PCR</cell></row><row><cell></cell><cell></cell><cell>Negative</cell><cell>Positive</cell><cell>Negative</cell><cell>Positive</cell><cell>Negative</cell><cell>Positive</cell><cell>Negative</cell><cell>Positive</cell><cell>Negative</cell><cell>Positive</cell></row><row><cell>HPV16 RNA</cell><cell>Negative</cell><cell>115</cell><cell>11</cell><cell>123</cell><cell>3</cell><cell>110</cell><cell>16</cell><cell>123</cell><cell>3</cell><cell>123</cell><cell>3</cell></row><row><cell></cell><cell>Positive</cell><cell>3</cell><cell>46</cell><cell>1</cell><cell>48</cell><cell>2</cell><cell>47</cell><cell>4</cell><cell>45</cell><cell>3</cell><cell>46</cell></row><row><cell>A-PCR</cell><cell>Negative</cell><cell></cell><cell></cell><cell>113</cell><cell>5</cell><cell>103</cell><cell>15</cell><cell>118</cell><cell>0</cell><cell>114</cell><cell>4</cell></row><row><cell></cell><cell>Positive</cell><cell></cell><cell></cell><cell>11</cell><cell>46</cell><cell>9</cell><cell>48</cell><cell>9</cell><cell>48</cell><cell>12</cell><cell>45</cell></row><row><cell>GP-PCR</cell><cell>Negative</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>110</cell><cell>14</cell><cell>121</cell><cell>3</cell><cell>124</cell><cell>0</cell></row><row><cell></cell><cell>Positive</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2</cell><cell>49</cell><cell>6</cell><cell>45</cell><cell>2</cell><cell>49</cell></row><row><cell>p16</cell><cell>Negative</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>112</cell><cell>0</cell><cell>112</cell><cell>0</cell></row><row><cell></cell><cell>Positive</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>15</cell><cell>48</cell><cell>14</cell><cell>49</cell></row><row><cell>p16 and A-PCR</cell><cell>Negative</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>123</cell><cell>4</cell></row><row><cell></cell><cell>Positive</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3</cell><cell>4 5</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc><div><p><s>Correlation of different methods for the determination of HPV status for the primary cohort (p &lt; 0.001 for all).</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell>A-PCR</cell><cell></cell><cell>GP-PCR</cell><cell></cell><cell>p16</cell><cell></cell><cell cols="2">p16 and A-PCR</cell><cell cols="2">p16 and GP-PCR</cell></row><row><cell></cell><cell></cell><cell>Negative</cell><cell>Positive</cell><cell>Negative</cell><cell>Positive</cell><cell>Negative</cell><cell>Positive</cell><cell>Negative</cell><cell>Positive</cell><cell>Negative</cell><cell>Positive</cell></row><row><cell>HPV16 RNA</cell><cell>Negative</cell><cell>78</cell><cell>3</cell><cell>77</cell><cell>4</cell><cell>77</cell><cell>4</cell><cell>81</cell><cell>0</cell><cell>80</cell><cell>1</cell></row><row><cell></cell><cell>Positive</cell><cell>0</cell><cell>9</cell><cell>0</cell><cell>9</cell><cell>0</cell><cell>9</cell><cell>0</cell><cell>9</cell><cell>0</cell><cell>9</cell></row><row><cell>A-PCR</cell><cell>Negative</cell><cell></cell><cell></cell><cell>75</cell><cell>3</cell><cell>74</cell><cell>4</cell><cell>78</cell><cell>0</cell><cell>77</cell><cell>1</cell></row><row><cell></cell><cell>Positive</cell><cell></cell><cell></cell><cell>2</cell><cell>10</cell><cell>3</cell><cell>9</cell><cell>3</cell><cell>9</cell><cell>3</cell><cell>9</cell></row><row><cell>GP-PCR</cell><cell>Negative</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>74</cell><cell>3</cell><cell>77</cell><cell>0</cell><cell>77</cell><cell>0</cell></row><row><cell></cell><cell>Positive</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3</cell><cell>10</cell><cell>4</cell><cell>9</cell><cell>3</cell><cell>10</cell></row><row><cell>p16</cell><cell>Negative</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>77</cell><cell>0</cell><cell>77</cell><cell>0</cell></row><row><cell></cell><cell>Positive</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>4</cell><cell>9</cell><cell>3</cell><cell>1 0</cell></row><row><cell>p16 and A-PCR</cell><cell>Negative</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>80</cell><cell>1</cell></row><row><cell></cell><cell>Positive</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0</cell><cell>9</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head></head><label></label><figDesc><div><p><s>Since there were no events in the HPV positive group, the Cox model did not converge.</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell cols="2">from distant metastases</cell><cell>Overall survival</cell><cell></cell></row><row><cell>Variable</cell><cell>HR (95% CI)</cell><cell>p-Value</cell><cell>HR (95% CI)</cell><cell>p-Value</cell><cell>HR (95% CI)</cell><cell>p-Value</cell></row><row><cell>Postoperative cohort</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Tumour localization, ECE status and</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>HPV16 RNA</cell><cell>0.23 (0.05-1.06)</cell><cell>0.059</cell><cell>0.17 (0.04-0.73)</cell><cell>0.018</cell><cell>0.24 (0.10-0.59)</cell><cell>0.002</cell></row><row><cell>A-PCR</cell><cell>0.19 (0.04-0.82)</cell><cell>0.027</cell><cell>0.41 (0.15-1.13)</cell><cell>0.086</cell><cell>0.35 (0.17-0.74)</cell><cell>0.006</cell></row><row><cell>GP-PCR</cell><cell>0.37 (0.10-1.35)</cell><cell>0.13</cell><cell>0.26 (0.07-0.90)</cell><cell>0.034</cell><cell>0.34 (0.15-0.75)</cell><cell>0.008</cell></row><row><cell>p16</cell><cell>0.26 (0.07-0.91)</cell><cell>0.036</cell><cell>0.27 (0.09-0.81)</cell><cell>0.019</cell><cell>0.40 (0.20-0.80)</cell><cell>0.010</cell></row><row><cell>p16 and A-PCR</cell><cell>0.12 (0.02-0.89)</cell><cell>0.039</cell><cell>0.18 (0.04-0.82)</cell><cell>0.026</cell><cell>0.34 (0.15-0.79)</cell><cell>0.012</cell></row><row><cell>p16 and GP-PCR</cell><cell>0.24 (0.05-1.11)</cell><cell>0.068</cell><cell>0.18 (0.04-0.78)</cell><cell>0.022</cell><cell>0.38 (0.17-0.85)</cell><cell>0.018</cell></row><row><cell>Primary cohort</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">N stage, tumour volume and</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>HPV16 RNA</cell><cell></cell><cell>*</cell><cell>0.38 (0.05-2.86)</cell><cell>0.35</cell><cell>0.26 (0.06-1.06)</cell><cell>0.061</cell></row><row><cell>A-PCR</cell><cell>0.12 (0.02-0.87)</cell><cell>0.036</cell><cell>0.61 (0.14-2.70)</cell><cell>0.52</cell><cell>0.41 (0.15-1.15)</cell><cell>0.089</cell></row><row><cell>GP-PCR</cell><cell>0.24 (0.06-0.98)</cell><cell>0.047</cell><cell>0.27 (0.04-2.02)</cell><cell>0.20</cell><cell>0.27 (0.08-0.86)</cell><cell>0.028</cell></row><row><cell>p16</cell><cell></cell><cell>*</cell><cell>0.25 (0.03-1.93)</cell><cell>0.19</cell><cell>0.16 (0.04-0.67)</cell><cell>0.012</cell></row><row><cell>p16 and A-PCR</cell><cell></cell><cell>*</cell><cell>0.38 (0.05-2.86)</cell><cell>0.35</cell><cell>0.26 (0.06-1.06)</cell><cell>0.061</cell></row><row><cell>p16 and GP-PCR</cell><cell></cell><cell>*</cell><cell>0.35 (0.05-2.69)</cell><cell>0.32</cell><cell>0.23 (0.06-0.95)</cell><cell>0.043</cell></row></table><note><p><s>*</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Please cite this article in press as: Linge A et al. Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. Radiother Oncol (2018), https://doi.org/10.1016/j.radonc.2017.12.007</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>The authors gratefully acknowledge the excellent technical assistance by Mrs. Liane Stolz-Kieslich, Mrs. Sigrid Balschukat and Mrs. Andrea Petzold.</s><s>The authors thank all pathologists, head and neck surgeons and maxillofacial surgeons at the eight treatment centres who provided tumour material and data for this study.</s><s>The study was financed by a Joint Funding Grant within the German Cancer Consortium (DKTK) awarded to the DKTK-ROG (principle investigator: Michael Baumann).</s><s>The DKTK is funded as one of the National German Health Centers by the Federal German Ministry of Education and Research (BMBF).</s><s>This work was also funded in part by BMBF 02NUK047C (BMBF ZiSStrans to KL).</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest</head><p><s>Volker Gudziol is a member of the advisory board of Bristol-Myers Squibb and received speaking fees from Roche Company.</s><s>Ute Ganswindt received speaking fees from MERCK Serono Travel.</s><s>The other authors have nothing to disclose.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Appendix A. Supplementary data</head><p><s>Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.radonc.2017.12.</s><s>007.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>8</head><p><s>HPV detection methods in HNSCC</s></p><p><s>Please cite this article in press as: Linge A et al.</s><s>Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC.</s><s>Radiother Oncol (2018), https://doi.org/10.1016/j.radonc.2017.12.007</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Estimates of worldwide burden of cancer in 2008: GLOBOCAN</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Shin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Forman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mathers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Parkin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="2893" to="2917" />
			<date type="published" when="2008">2008. 2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">HPV-associated head and neck cancer: a virus-related cancer epidemic</title>
		<author>
			<persName><forename type="first">S</forename><surname>Marur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Souza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Westra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Forastiere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="781" to="789" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Human papillomavirus and rising oropharyngeal cancer incidence in the United States</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Chaturvedi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Engels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Pfeiffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">Y</forename><surname>Hernandez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="4294" to="4301" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Human papillomavirus and survival of patients with oropharyngeal cancer</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Ang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wheeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Weber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">363</biblScope>
			<biblScope unit="page" from="24" to="35" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Biological basis for increased sensitivity to radiation therapy in HPV-positive head and neck cancers</title>
		<author>
			<persName><forename type="first">V</forename><surname>Bol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Gregoire</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biomed Res Int</title>
		<imprint>
			<biblScope unit="page">696028</biblScope>
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity</title>
		<author>
			<persName><forename type="first">T</forename><surname>Rieckmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tribius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Grob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Meyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiother Oncol</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="242" to="246" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck</title>
		<author>
			<persName><forename type="first">P</forename><surname>Lassen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Eriksen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hamilton-Dutoit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tramm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Alsner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Overgaard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="1992" to="1998" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">The influence of HPVassociated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&amp;7 trial</title>
		<author>
			<persName><forename type="first">P</forename><surname>Lassen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Eriksen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Krogdahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Therkildsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiother Oncol</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="49" to="55" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma</title>
		<author>
			<persName><forename type="first">K</forename><surname>Lindel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Beer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Laissue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Greiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Aebersold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="805" to="813" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Impact of HPVassociated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer</title>
		<author>
			<persName><forename type="first">P</forename><surname>Lassen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Primdahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Johansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Kristensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiother Oncol</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="310" to="316" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)</title>
		<author>
			<persName><forename type="first">A</forename><surname>Linge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lohaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Löck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nowak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiother Oncol</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="364" to="373" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)</title>
		<author>
			<persName><forename type="first">F</forename><surname>Lohaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Linge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Tinhofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Budach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiother Oncol</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="317" to="323" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced HNSCC after postoperative radiotherapy</title>
		<author>
			<persName><forename type="first">A</forename><surname>Linge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Löck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Krenn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Appold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Transl Radiat Oncol</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="19" to="26" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">The future of personalised radiotherapy for head and neck cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Caudell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Torres-Roca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Gillies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Enderling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="e266" to="e273" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Radiation oncology in the era of precision medicine</title>
		<author>
			<persName><forename type="first">M</forename><surname>Baumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Overgaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Debus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="234" to="249" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial</title>
		<author>
			<persName><forename type="first">C</forename><surname>Fakhry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Westra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cmelak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="261" to="269" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Human papillomavirusassociated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Salazar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">V</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Garg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Haigentz</forename><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Head Neck Pathol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="77" to="87" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes</title>
		<author>
			<persName><forename type="first">S</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Schmidt-Grimminger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Murant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Broker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Chow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genes Dev</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="2335" to="2349" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Inhibition of cyclin D-CDK4/ CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">N</forename><surname>Khleif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Degregori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Yee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Otterson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="4350" to="4354" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">The molecular mechanism of human papillomavirusinduced carcinogenesis in head and neck squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">D</forename><surname>Sano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Oridate</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="819" to="826" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">The Rb/E2F pathway and cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Nevins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Mol Genet</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="699" to="703" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Smeets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Hesselink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Speel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Haesevoets</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="2465" to="2472" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Detection of human papillomavirus (HPV) in clinical samples: evolving methods and strategies for the accurate determination of HPV status of head and neck carcinomas</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Westra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oral Oncol</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="771" to="779" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Prigge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Arbyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Von Knebel Doeberitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Reuschenbach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">140</biblScope>
			<biblScope unit="page" from="1186" to="1198" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Bishop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">J</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Luo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Surg Pathol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="1874" to="1882" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">The use of general primers GP5 and GP6 elongated at their 3&apos; ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>De Roda Husman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Walboomers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Van Den Brule</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Meijer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Snijders</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Gen Virol</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="1057" to="1062" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Snijders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Van Den Brule</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">F</forename><surname>Schrijnemakers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Snow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Meijer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Walboomers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Gen Virol</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="173" to="181" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Low cancer stem cell marker expression and low hypoxia identify good prognosis subgroups in HPV(-) HNSCC after postoperative radiochemotherapy: a multicenter study of the DKTK-ROG</title>
		<author>
			<persName><forename type="first">A</forename><surname>Linge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Löck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Gudziol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nowak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="2639" to="2649" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">p16 expression as a surrogate marker for HPVrelated oropharyngeal carcinoma: a guide for interpretative relevance and consistency</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>El-Naggar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Westra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Head Neck</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="459" to="461" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Jordan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Lingen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Perez-Ordonez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>He</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Surg Pathol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="945" to="954" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Schache</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Liloglou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Risk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Filia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="6262" to="6271" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">HPV-related squamous cell carcinoma of the head and neck: An update on testing in routine pathology practice</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Bishop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lewis</forename><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Rocco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Faquin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Diagn Pathol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="344" to="351" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Singhi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Westra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="2166" to="2173" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Evidence for a causal association between human papillomavirus and a subset of head and neck cancers</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Gillison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Koch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Capone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Spafford</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="709" to="720" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Molecular characterization of p16-immunopositive but HPV DNA-negative oropharyngeal carcinomas</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Rietbergen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Snijders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Beekzada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Braakhuis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="2366" to="2372" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: a multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG)</title>
		<author>
			<persName><forename type="first">P</forename><surname>Balermpas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rödel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rödel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krause</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="page" from="171" to="181" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">HPV and beyond-looking out for biomarkers for distinguishing the good prognosis from the bad prognosis group in locally advanced and clinically high risk HNSCC</title>
		<author>
			<persName><forename type="first">F</forename><surname>Lohaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Linge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baumann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Transl Med</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">255</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation</title>
		<author>
			<persName><forename type="first">I</forename><surname>Tinhofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Budach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Saki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Konschak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="78" to="86" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)</title>
		<author>
			<persName><forename type="first">P</forename><surname>Balermpas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rödel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Linge</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page" from="594" to="603" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy</title>
		<author>
			<persName><forename type="first">C</forename><surname>De-Colle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mönnich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Welz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Boeke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Transl Radiat Oncol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="28" to="36" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
